Derivation of pluripotent epiblast stem cells from mammalian embryos
NATURE
Authors: Brons, I. Gabrielle M.; Smithers, Lucy E.; Trotter, Matthew W. B.; Rugg-Gunn, Peter; Sun, Bowen; de Sousa Lopes, Susana M. Chuva; Howlett, Sarah K.; Clarkson, Amanda; Ahrlund-Richter, Lars; Pedersen, Roger A.; Vallier, Ludovic
Abstract
Although the first mouse embryonic stem (ES) cell lines were derived 25 years ago(1,2) using feeder-layer-based blastocyst cultures, subsequent efforts to extend the approach to other mammals, including both laboratory and domestic species, have been relatively unsuccessful. The most notable exceptions were the derivation of non-human primate ES cell lines(3) followed shortly thereafter by their derivation of human ES cells(4). Despite the apparent common origin and the similar pluripotency of mouse and human embryonic stem cells, recent studies have revealed that they use different signalling pathways to maintain their pluripotent status. Mouse ES cells depend on leukaemia inhibitory factor and bone morphogenetic protein, whereas their human counterparts rely on activin (INHBA)/nodal (NODAL) and fibroblast growth factor (FGF). Here we show that pluripotent stem cells can be derived from the late epiblast layer of post-implantation mouse and rat embryos using chemically defined, activin-containing culture medium that is sufficient for long-term maintenance of human embryonic stem cells. Our results demonstrate that activin/Nodal signalling has an evolutionarily conserved role in the derivation and the maintenance of pluripotency in these novel stem cells. Epiblast stem cells provide a valuable experimental system for determining whether distinctions between mouse and human embryonic stem cells reflect species differences or diverse temporal origins.
Activin A regulation under global hypoxia in developing mouse brain
BRAIN RESEARCH
Authors: Brackmann, Florian A.; Link, Andrea S.; Jung, Susan; Richter, Mandy; Zoglauer, Daniel; Walkinshaw, Gail; Alzheimer, Christian; Trollmann, Regina
Abstract
Activin A is a multifunctional growth and differentiation factor with pronounced neuroprotective properties that is strongly up-regulated in various forms of acute brain disorders and injuries including epilepsy, stroke and trauma. In a pediatric context, activin A has been advanced as a potential marker for the severity of perinatal hypoxic-ischemic brain injury. Here we investigated the regulation of activin A under global hypoxia without ischemia in primary cultures of cortical neurons and in neonatal and adult mice of two strains (C57B1/6 and CD-1). From birth to adulthood, activin beta A subunit, activin receptors, and functional activin antagonists were all expressed at roughly similar mRNA levels in the brain of C57B1/6 mice. Independent of mouse line and age, we found both moderate (11% O-2, 2 h) and severe hypoxia (8%, 6 h) to be consistently associated with normal or even reduced levels of activin beta A (Inhba) mRNA. The surprising unresponsiveness of Inhba expression to hypoxia was confirmed at the protein level. In situ hybridization did not indicate regional, hypoxia-related differences in Inhba expression. Pharmacologic stabilization of hypoxia inducible factors with the prolyl hydroxylase inhibitor FG-4497 did not influence Inhba mRNA levels in neonatal mice. Our data indicate that pure hypoxia differs from other, more complex types of brain damage in that it appears not to recruit activin A as an endogenous neuroprotective agent. (C) 2013 Elsevier B.V. All rights reserved.